![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 20, 2017 3:38:23 PM
He states:
“Bryostatin by Neurotrope (OTCQB:NTRPD) downregulates protein kinase C alpha and protein kinase C alpha is the linchpin in the initial production of inflammation and oxidation in Alzheimer's disease (bryostatin's effect, protein kinase C alpha). However, due to damage to upstream receptors in most people with Alzheimer's disease, protein kinase C alpha activity decreases as the disease progresses (study). So it is not likely that bryostatin can be used to help most people at least not past a certain stage.”
His statement is not backed up by any reference citing research to prove his point. It is clearly only his opinion and not in any way reflects scientific thought into the multi modal effects of Byrostatin.
http://seekingalpha.com/article/4054680-alzheimers-disease-next
I would rather listen to the principal researcher in the field, Dr. Alkon:
My notes from Dr. Alkon’s BIO CEO presentation 02/13/17:
Minute 17:54: I do want to say that Bryostatin is one of a platform of drugs that we have. It is our lead compound now because it has experience in the patient population and we know it’s well tolerated. But we have 40 or so other compounds some of which are even more potent and even more specific and have proprietary composition of matter protection which we can use for second and third generation of drugs.
Minute 23: (Bryostatin) is well positioned to virtually…take care of every major aspect of this disease. So it is multi modal, multi modal means that we can look at prevention, slowing down progression, and actual reversal of Alzheimer’s disease. Which is what is in our current Phase 2 trial.
Minute 25:45 (refer to Slide 40 – Bryostaten Compassionate Use Program: Severe Alzheimer’s Disease “No other reports have ever shown comparable benefits in such severely demented patients”) These are our compassionate use patients…we saw major reversal of disease that’s why we teed-up our Phase 2 trial in the way we did for severe (Alzheimer’s) patients to see reversal. To see not just a reduction in the rate of decline…but a flipping, a changing of the sign of what happens, for example, with the preferred metric of advanced Alzheimer’s disease, the Severe Impairment Battery.
https://www.veracast.com/webcasts/bio/ceoinvestor2017/18111483071.cfm
Recent SNPX News
- Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:18 PM
- Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's • PR Newswire (US) • 12/06/2023 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/14/2023 10:05:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:23 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/03/2023 09:00:19 PM
- Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology • PR Newswire (US) • 11/02/2023 01:00:00 PM
- Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease • PR Newswire (US) • 09/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:05:55 PM
- Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study • PR Newswire (US) • 09/07/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:00:40 PM
- Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 07/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 12:55:57 PM
- Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience • PR Newswire (US) • 07/13/2023 01:00:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM